Sydney, 4 December 2017: Noxopharm Limited (NOX:ASX) has become aware of information circulating in the market about an abscopal anti-cancer response in a patient receiving the Company’s experimental drug, NOX66, provided under the Company’s Compassionate Use Scheme.
Under ASX continuance disclosure rules, the Company feels obliged to respond to that information.
For further information please download PDF attached:
Download this document
